How are PVLA strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PVLA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 58.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,015.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a PVLA strangle?

The breakeven for the PVLA strangle priced on this page is roughly $134.85 and $170.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PVLA market-implied 1-standard-deviation expected move is approximately 16.89%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current PVLA implied volatility affect this strangle?

PVLA ATM IV is at 58.90% with IV rank near 1.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

PVLA Strangle Strategy

PVLA (Palvella Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

PVLA (Palvella Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.75B, a beta of -0.14 versus the broader market, a 52-week range of 21.55-151.18, average daily share volume of 247K, a public-listing history dating back to 2015, approximately 14 full-time employees. These structural characteristics shape how PVLA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.14 indicates PVLA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on PVLA?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current PVLA snapshot

As of June 29, 2026, spot at $152.87, ATM IV 58.90%, IV rank 1.94%, expected move 16.89%. The strangle on PVLA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on PVLA specifically: PVLA IV at 58.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a PVLA strangle, with a market-implied 1-standard-deviation move of approximately 16.89% (roughly $25.81 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PVLA expiries trade a higher absolute premium for lower per-day decay. Position sizing on PVLA should anchor to the underlying notional of $152.87 per share and to the trader's directional view on PVLA stock.

PVLA strangle setup

The PVLA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PVLA near $152.87, the first option leg uses a $160.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PVLA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PVLA shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$160.00	$6.00
Buy 1	Put	$145.00	$4.15

PVLA strangle risk and reward

Net Premium / Debit: -$1,015.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$1,015.00
Breakeven(s): $134.85, $170.15
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

PVLA strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on PVLA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$13,484.00
$33.81	-77.9%	+$10,104.07
$67.61	-55.8%	+$6,724.14
$101.41	-33.7%	+$3,344.21
$135.21	-11.6%	-$35.72
$169.01	+10.6%	-$114.35
$202.81	+32.7%	+$3,265.58
$236.61	+54.8%	+$6,645.51
$270.40	+76.9%	+$10,025.44
$304.20	+99.0%	+$13,405.37

When traders use strangle on PVLA

Strangles on PVLA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PVLA chain.

PVLA thesis for this strangle

The market-implied 1-standard-deviation range for PVLA extends from approximately $127.06 on the downside to $178.68 on the upside. A PVLA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PVLA IV rank near 1.94% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PVLA at 58.90%. As a Healthcare name, PVLA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PVLA-specific events.

PVLA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PVLA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PVLA alongside the broader basket even when PVLA-specific fundamentals are unchanged. Always rebuild the position from current PVLA chain quotes before placing a trade.

Frequently asked questions

What is a strangle on PVLA?: A strangle on PVLA is the strangle strategy applied to PVLA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PVLA stock trading near $152.87, the strikes shown on this page are snapped to the nearest listed PVLA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are PVLA strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PVLA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 58.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,015.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PVLA strangle?: The breakeven for the PVLA strangle priced on this page is roughly $134.85 and $170.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PVLA market-implied 1-standard-deviation expected move is approximately 16.89%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on PVLA?: Strangles on PVLA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PVLA chain.
How does current PVLA implied volatility affect this strangle?: PVLA ATM IV is at 58.90% with IV rank near 1.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.